-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to industry forecasts, the demand for antithrombotic drugs in the global market will continue to increase in the future, and the entire antithrombotic drug industry is expected to expand
.
The domestic antithrombotic drug structure is gradually approaching the global market, becoming a new growth point for the antithrombotic drug industry
.
It is expected that China's antithrombotic drug market is expected to achieve rapid growth in the medium and long term
.
From the current point of view, many domestic companies have entered the antithrombotic drug industry track, and the market competition is fierce, and most companies are using generic drugs to seize the market
.
It is reported that recently, some companies have announced that antithrombotic drugs have passed the consistency evaluation to provide patients with new choices
.
For example, Sihuan Pharmaceutical recently announced that the antithrombotic drug ticagrelor tablets (60 mg and 90 mg) developed by the group have been approved for drug registration issued by the China National Medical Products Administration, which is deemed to have the same quality and efficacy as a generic drug.
Sexual evaluation
.
The data show that ticagrelor is a new type of antithrombotic drug, which is a class B (2021) drug of China's national medical insurance, and is used for patients with acute coronary syndrome (ACS) or a history of myocardial infarction with at least one artery Reduced rates of cardiovascular death, myocardial infarction, and stroke in patients with high risk factors for atherothrombotic events
.
Ticagrelor does not need to undergo liver metabolic activation, and has the characteristics of rapidity and potency.
It is recommended by many domestic and foreign treatment guidelines and has great market potential
.
According to IQVIA data, from 2017 to 2020, the domestic sales of ticagrelor in China increased year by year, with a compound annual growth rate of 61.
46%.
The sales in these four years were RMB 4.
2, 8.
7, 1.
61, and 1.
78 billion, respectively
.
Sihuan Pharmaceutical stated that the anti-thrombotic field is the key area of the Group’s deployment.
The product has been awarded the “Drug Registration Certificate”, which will further benefit the majority of patients.
Future market sales and market competition will have a positive impact on the Group's operating performance
.
In addition to Sihuan Pharmaceutical, the supplementary application for consistency evaluation of the antithrombotic drug Fondaparinux Sodium Injection submitted by Yangzijiang Pharmaceuticals was approved recently, becoming the 4th company to pass the evaluation. .
The data show that fondaparinux is a synthetic specific inhibitor of activated factor Xa.
It is clinically used to prevent venous thromboembolism in patients undergoing major orthopedic surgery of the lower extremity, such as hip fracture, major knee surgery or hip replacement.
occurrence of the event
.
The product was developed by GlaxoSmithKline, and its sales in China's national hospital market will exceed 200 million yuan in 2020.
In 2021, H1 sales will increase by 350% year-on-year, and the total annual sales may exceed 500 million yuan
.
At present, a total of 6 domestic companies have been approved to produce this product, including 1 importer Aspen; 5 domestic companies, namely Hengrui Pharmaceutical, Borui Pharmaceutical, Haisco, Zhaoke Pharmaceutical, Nanjing Jianyou,
etc.
In addition, it is understood that the antithrombotic injection Argatroban Injection of Yangzijiang Pharmaceutical Group Guangzhou Hairui Pharmaceutical Co.
, Ltd.
has been accepted as a 4-type imitation
.
The data show that the drug is a synthetic arginine derivative, which can inhibit the activity of thrombin, thereby producing an anticoagulant effect
.
Analysts pointed out that in recent years, with the aging of the population, the change of people's living habits, the acceleration of life rhythm and the increase of pressure, the number of patients with cardiovascular and cerebrovascular diseases has increased year by year, which has also promoted the market demand for antithrombotic drugs.
expansion
.
From the current point of view, local companies have performed well in the field of generic antithrombotic drugs, but in the field of original drug research, there is a certain gap between local antithrombotic drug companies and international drug companies, and there is still a lot of room for growth in the domestic market
.
.
The domestic antithrombotic drug structure is gradually approaching the global market, becoming a new growth point for the antithrombotic drug industry
.
It is expected that China's antithrombotic drug market is expected to achieve rapid growth in the medium and long term
.
From the current point of view, many domestic companies have entered the antithrombotic drug industry track, and the market competition is fierce, and most companies are using generic drugs to seize the market
.
It is reported that recently, some companies have announced that antithrombotic drugs have passed the consistency evaluation to provide patients with new choices
.
For example, Sihuan Pharmaceutical recently announced that the antithrombotic drug ticagrelor tablets (60 mg and 90 mg) developed by the group have been approved for drug registration issued by the China National Medical Products Administration, which is deemed to have the same quality and efficacy as a generic drug.
Sexual evaluation
.
The data show that ticagrelor is a new type of antithrombotic drug, which is a class B (2021) drug of China's national medical insurance, and is used for patients with acute coronary syndrome (ACS) or a history of myocardial infarction with at least one artery Reduced rates of cardiovascular death, myocardial infarction, and stroke in patients with high risk factors for atherothrombotic events
.
Ticagrelor does not need to undergo liver metabolic activation, and has the characteristics of rapidity and potency.
It is recommended by many domestic and foreign treatment guidelines and has great market potential
.
According to IQVIA data, from 2017 to 2020, the domestic sales of ticagrelor in China increased year by year, with a compound annual growth rate of 61.
46%.
The sales in these four years were RMB 4.
2, 8.
7, 1.
61, and 1.
78 billion, respectively
.
Sihuan Pharmaceutical stated that the anti-thrombotic field is the key area of the Group’s deployment.
The product has been awarded the “Drug Registration Certificate”, which will further benefit the majority of patients.
Future market sales and market competition will have a positive impact on the Group's operating performance
.
In addition to Sihuan Pharmaceutical, the supplementary application for consistency evaluation of the antithrombotic drug Fondaparinux Sodium Injection submitted by Yangzijiang Pharmaceuticals was approved recently, becoming the 4th company to pass the evaluation. .
The data show that fondaparinux is a synthetic specific inhibitor of activated factor Xa.
It is clinically used to prevent venous thromboembolism in patients undergoing major orthopedic surgery of the lower extremity, such as hip fracture, major knee surgery or hip replacement.
occurrence of the event
.
The product was developed by GlaxoSmithKline, and its sales in China's national hospital market will exceed 200 million yuan in 2020.
In 2021, H1 sales will increase by 350% year-on-year, and the total annual sales may exceed 500 million yuan
.
At present, a total of 6 domestic companies have been approved to produce this product, including 1 importer Aspen; 5 domestic companies, namely Hengrui Pharmaceutical, Borui Pharmaceutical, Haisco, Zhaoke Pharmaceutical, Nanjing Jianyou,
etc.
In addition, it is understood that the antithrombotic injection Argatroban Injection of Yangzijiang Pharmaceutical Group Guangzhou Hairui Pharmaceutical Co.
, Ltd.
has been accepted as a 4-type imitation
.
The data show that the drug is a synthetic arginine derivative, which can inhibit the activity of thrombin, thereby producing an anticoagulant effect
.
Analysts pointed out that in recent years, with the aging of the population, the change of people's living habits, the acceleration of life rhythm and the increase of pressure, the number of patients with cardiovascular and cerebrovascular diseases has increased year by year, which has also promoted the market demand for antithrombotic drugs.
expansion
.
From the current point of view, local companies have performed well in the field of generic antithrombotic drugs, but in the field of original drug research, there is a certain gap between local antithrombotic drug companies and international drug companies, and there is still a lot of room for growth in the domestic market
.
